OUR SCIENCE
Our scientists have identified a key protein in one of the main T-cell activation mechanisms. By introducing our enhanced version of this protein into T cells, we can significantly boost their activation while maintaining safety through antigen dependency.
This breakthrough has the potential to address the major limitations of current T-cell therapies and significantly improve clinical outcomes in solid tumors, hematological cancers, and auto-immune diseases.
Unlocking the full potential of T-cell therapies
Optimized activation in low immunogenic microenvironment
Increased activation and proliferation upon antigen exposure
Increased sensitivity to low antigen expression
Maintained dependence on antigen stimulation
Resistance to immune checkpoints
Our technology is applicable to any T-cell therapy platform, including CAR-T cells, TCR, HIT & STAR-engineered T cells, TILs, and CAR-Tregs.
Ongoing programs
Our initial focus includes developing enhanced CAR-T cell therapies for solid tumors and auto-immune diseases.
We are also actively seeking partners to expand the impact of our technology across various T-cell therapeutic platforms, notably in TILs, TCR-T cells, and CAR-Treg cells.